Fighting drug resistance with fast, artificial enhancement of natural products
Credit: Image by Caitlin Devor, The University of Tokyo, CC-BY
Researchers in Japan have identified multiple promising new drug candidates to treat antibiotic-resistant infections, including the superbug MRSA (methicillin-resistant Staphylococcus aureus). The team developed a new technique to enhance the infection-fighting potential of natural chemicals and test them quickly.
In laboratory tests, three of the synthetic molecules that the researchers built are four times more effective at killing bacteria than their natural predecessor, which is itself already an order of magnitude more potent than the current drug used against MRSA, vancomycin.
“Our technique is fast because we can build thousands of new molecules in a single synthesis,” said Assistant Professor Hiroaki Itoh from the University of Tokyo Department of Pharmaceutical Sciences.
Researchers first identified the promising new natural antibiotic from a soil sample collected in the subtropical island of Okinawa in southwestern Japan. The antibiotic, called lysocin E, has a unique mechanism of killing bacteria compared to the currently available classes of antibiotics. Even MRSA would be defenseless against it.
Lysocin E has a complex chemical structure that resembles a tambourine: a large ring with 12 short side chains.
The protein building blocks, called amino acids, which form those chains, each contribute to the overall function of the entire molecule. Swapping the naturally occurring amino acids for different ones could enhance the function of the antibiotic.
“We try to find the improvements that natural selection did not make yet,” said Itoh.
Researchers focused on four side chains and tested how seven different amino acids might enhance lysocin E’s antibacterial activity. All possible combinations of the four side chains and seven amino acids meant that researchers needed to build 2,401 different synthetic versions of modified lysocin E.
Researchers built all 2,401 modified lysocin E simultaneously, one amino acid at a time on top of tiny beads. The beads were divided into seven portions each time researchers reached a part of the molecule where they wanted to vary the amino acid in a side chain. Then all the beads were recombined until researchers reached the location of the next amino acid variation.
“Very few researchers have done this before because many naturally occurring molecules have relatively large and complex structures. This makes them difficult to build synthetically,” explained Itoh.
The technique is known as one-bead-one-compound library strategy or split-and-mix synthesis.
Once all 2,401 modified lysocin E were built, researchers tested if they retained the natural version’s unique method of killing bacteria. Researchers then removed the molecules from the beads and identified their chemical structures.
Only 22 modified lysocin E were selected for the final round of tests to measure how effective they were at killing six common bacteria in tiny test tubes. Of those, 11 modified lysocin E showed antimicrobial activity better or equal to the original lysocin E.
Researchers will study the three most potent modified lysocin E – defined by the very small amount of drug effective at killing bacteria – to verify their effectiveness at treating infections in nonhuman animal models and to understand the detailed mechanism of how they kill bacteria at such low doses.
“Potentially, our method could be used to find other drug candidates based on promising small protein natural products, including for anti-cancer or anti-virus,” said Itoh.
Researchers are confident that their method of synthetically enhancing natural products can increase the speed of early-stage drug discovery, and help maximize the potential of naturally occurring complex molecules.
Besides bacteria, pathogens including HIV (a virus) and malaria (a parasite) are becoming resistant to medications, increasing the potential global health threat of drug resistance. For more information on antibiotic resistance, see the World Health Organization fact sheet:
Hiroaki Itoh, Kotaro Tokumoto, Takuya Kaji, Atmika Paudel, Suresh Panthee, Hiroshi Hamamoto, Kazuhisa Sekimizu, Masayuki Inoue. Development of a high-throughput strategy for discovery of potent analogues of antibiotic lysocin E. 5 July 2019. Nature Communications. DOI: 10.1038/s41467-019-10754-4.
Related Research Article
Hamamoto H, Urai M, Ishii K, Yasukawa J, Paudel A, Murai M, Kaji T, Kuranaga T, Hamase K, Katsu T, Su J, Adachi T, Uchida R, Tomoda H, Yamada M, Souma M, Kurihara H, Inoue M, Sekimizu K. Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Dec 2014. Nature Chemical Biology. DOI: 10.1038/nchembio.1710
Inoue Laboratory: http://www.
Graduate School of Pharmaceutical Sciences: http://www.
Professor Masayuki Inoue
Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033, JAPAN
Email: [email protected]
Ms. Caitlin Devor
Division for Strategic Public Relations, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, JAPAN
Email: [email protected]
About the University of Tokyo
The University of Tokyo is Japan’s leading university and one of the world’s top research universities. The vast research output of some 6,000 researchers is published in the world’s top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 2,000 international students. Find out more at http://www.
Related Journal Article